NCT05455320: Phase 3 - (Talquetamab) Tal-DP Vs Tal-D Vs DPd - RRMM -Multiple Myeloma (MonumenTAL-3)
Updated: Feb 4
NCT05455320: Phase 3: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MonumenTAL-3)
NCT05455320: Phase 3: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MonumenTAL-3)
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab in combination with pomalidomide and dexamethasone (DPd).
Sponsor
ClinicalTrials.gov Identifier: NCT05455320
Official Title: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Daratumumab (SC) and Pomalidomide (Tal-DP) or Talquetamab (SC) in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy
First Posted : July 13, 2022
Click here to see details on ClinicalTrials.gov
Talquetamab (Code C171840)
Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564
GPRC5D x CD3 Bispecific Antibody JNJ-64407564
GPRC5D x CD3 DuoBody Antibody JNJ-64407564
GPRC5D/CD3 DuoBody Antibody JNJ-64407564
Humanized GPRC5D x CD3 DuoBody Antibody JNJ-64407564
JNJ 64407564
JNJ-64407564
JNJ64407564
Talquetamab
TALQUETAMAB
Drug: Talquetamab
Drug: Daratumumab
Drug: Pomalidomide
Drug: Dexamethasone
Locations
United States, Arizona
United States, Arkansas
United States, California
United States, District of Columbia
United States, Florida
United States, Georgia
United States, Kansas
United States, Louisiana
United States, Maryland
United States, Massachusetts
United States, Michigan
United States, Mississippi
United States, Missouri
United States, New York
United States, North Carolina
United States, Ohio
United States, Pennsylvania
United States, Tennessee
United States, Texas
United States, Virginia
United States, Washington
Asia
Europe
Belgium
Brazil
China
Czechia
France
Germany
Greece
Italy
Japan
Korea, Republic of
Netherlands
Poland
Spain
Taiwan
Turkey
United Kingdom
RELATED POSTS
TECLISTAMAB STUDIES:
NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)
NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - (MajesTEC-3)
NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)
TALQUETAMAB STUDIES:
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma
TECLISTAMAB AND TALQUETAMAB STUDIES:
NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma
NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2
Commentaires